21 May 2009
Living donor kidney transplantation (LDKT) – 10 years single centre experience
A Chamienia, A Dębska-Ślizień, B Rutkowski, G Moszkowska, D Zadrożny, Z ŚledzińskiAnn Transplant 2009; 14(1): 59-59 :: ID: 880522
Abstract
Background: Kidney transplantation (KT) is considered the best treatment option for most patients with chronic renal failure. Available data show that living donor KT (LDKT) is a viable option in transplantation characterized by better short and long term results. In Poland number of LDKT is very low and accounts for between 2 and 3% of all KT performed.
Material/Methods: We present here 10 years of LDKT experience in a single centre between 1999 and 2009. There were 23 LDKT performed during this period, which accounts for 3.3% of all KT in this period.
Results: Most (83%) were living related donor KT. Mean recipient's age was
33±11 years and mean donor's age was 48±7 years. Most donors were women (15-65%). In most but 3 cases the LDKT was a fi rst transplant. Mean number of HLA class I and II mismatches was 3.2±1.3. Mean cold ischemia time was 167±51 min. and warm ischemia time 37±36 min. 4 recipients (17.4%) received ATG induction and 3 (13%) daclizumab induction. 34% of recipients were placed on cyclosporin based immunosuppression and remaining 66% on tacrolimus. 59% received mycophenolate mofetil. All recipients received steroids. Delayed graft function was observed in 3 cases and in 4 cases acute rejection was diagnosed. One year patient's and graft's survival were both 100%. Five year patient's and graft's survival were 100% and 93%, respectively. The mean serum creatinine levels at hospital discharge, 6 months, 1 and 5 years after KT were 1.91±0.4, 1.7±0.3, 1.55±0.4 and 1.64±1.09 mg/dl, respectively.
Conclusions: Our results confi rm excellent outcomes reported previously in
LDKT. This form of KT should be actively promoted in our country.
Keywords: Kidney Transplantation, Living Donors
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






